Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Oct 10;114(12):4747–4762. doi: 10.1111/cas.15989

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

DLGAP1‐AS2 is overexpressed in osteosarcoma (OS) and DLGAP1‐AS2 depletion restrains OS cell malignancies. (A) DLGAP1‐AS2 level in sarcoma tissues (n = 259) and non‐tumor tissues (n = 2) shown by TCGA. (B) RT‐qPCR and (C) ISH analyses of DLGAP1‐AS2 level in OS tissues and adjacent normal tissues. (D) DLGAP1‐AS2 expression in OS cell lines and hFOB 1.19 cells measured by RT‐qPCR. (E) Knockdown efficiency of DLGAP1‐AS2 measured by RT‐qPCR. (F) Impact of silencing DLGAP1‐AS2 on OS cell proliferation determined by EdU assay. (G) Impact of silencing DLGAP1‐AS2 on OS cell apoptosis evaluated by TUNEL assay. (H) Impact of silencing DLGAP1‐AS2 on OS cell migration tested by wound healing assay. (I) Impact of silencing DLGAP1‐AS2 on OS cell invasion detected by Transwell assay. (J) Western blotting of the protein levels of EMT‐related markers in OS cell lines. **p < 0.01, ***p < 0.001.